Artificial neural network systems to predict the response to sintilimab in squamous-cell non-small-cell lung cancer based on data of ORIENT-3 study.

Journal: Cancer immunology, immunotherapy : CII
PMID: 39708123

Abstract

BACKGROUND: Existing biomarkers and models for predicting response to programmed cell death protein 1 monoclonal antibody in advanced squamous-cell non-small cell lung cancer (sqNSCLC) did not have enough accuracy. We used data from the ORIENT-3 study to construct artificial neural network (ANN) systems to predict the response to sintilimab for sqNSCLC.

Authors

  • Tongji Xie
    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
  • Guangyu Fan
    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
  • Le Tang
    National Engineering Research Center for Agro-Ecological Big Data Analysis & Application, Anhui University, Hefei 230601, People's Republic of China.
  • Puyuan Xing
    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. xingpuyuan@cicams.ac.cn.
  • Yuankai Shi
    Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Clinical Study On Anticancer Molecular Targeted Drugs, No.17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China. syuankai@cicams.ac.cn.

Keywords

External Resources

Popular Topics
Recent Journals